BIOVENTIX PLC

Delisting Announcement • Apr 29, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

BIOVENTIX PLC - Admission to AIM

PR Newswire

London, April 29

                             Bioventix plc                        ("Bioventix" or the "Company")                               Admission to AIMThe Board of Bioventix plc (AIM: BVXP) is pleased to announce the admissiontoday of the Company's ordinary shares to trading on the AIM Market of theLondon Stock Exchange ("AIM").finnCap are Nominated Adviser and Broker to the Company. Further information onthe Company, including the Admission document and AIM Rule 26 information, isdetailed on the Company's website, www.bioventix.com.Peter Harrison, Chief Executive Officer of Bioventix, commented: "I amdelighted Bioventix has joined AIM. This will support the Company's next phaseof growth and provide improved liquidity in the Company's shares for bothexisting and new investors. I would like to thank our shareholders for theirsupport while we were traded on ISDX and look forward to the future withconfidence."For further information please contact:Bioventix plc                                       Tel: 01252 728 001Peter Harrison           Chief Executive OfficerfinnCap Ltd                                         Tel: 020 7220 0500Geoff Nash/Simon Hicks   Corporate FinanceSteve Norcross           Corporate BrokingAbout Bioventix plc:Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on ISDX under the symbol BVXP.